Core Viewpoint - Inven Bio-B (09606) has seen a significant stock price increase, attributed to recent regulatory approvals for its drug DB-1418, which targets advanced non-small cell lung cancer [1] Group 1: Stock Performance - Inven Bio-B's stock rose over 8%, currently trading at 329.6 HKD with a trading volume of 658 million HKD [1] Group 2: Regulatory Approvals - On November 11, Inven Bio announced that DB-1418 received Fast Track designation from the US FDA for treating unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] - On November 12, the China National Medical Products Administration (NMPA) publicly announced the clinical approval of DB-1418 for treating advanced/metastatic malignant solid tumors [1] Group 3: Collaboration and Financials - Earlier in January, Inven Bio entered a global development collaboration with Avenzo Therapeutics for the bispecific ADC product AVZO-1418/DB-1418, which targets EGFR/HER3 [1] - Under the agreement, Inven Bio received a 50 million USD upfront payment and is eligible for up to 1.15 billion USD in milestone payments related to development, registration, and commercialization [1] - Inven Bio is also entitled to a share of sales revenue from Avenzo within its region [1]
港股异动 | 映恩生物-B(09606)再涨超8% DB-1418获FDA授予快速通道资格 同时在中国获批临床